Biologically Active Small Molecules

An elongation product of &gamma-linolenic acid (18:3), rapidly metabolized by fatty acid desaturases to produce arachidonic acid (20:4) metabolized through the cyclooxygenase pathway to produce 1-series prostaglandins can reduce atopic dermatitis

An internal standard for the quantification of DGLA by GC- or LC-MS.

An internal standard for the quantification of DGLA by GC- or LC-MS.

An internal standard for the quantification of DGLA by GC- or LC-MS.

An internal standard for the quantification of DGLA by GC- or LC-MS.

An endocannabinoid containing dihomo-&gamma-linoleate in place of the arachidonate moiety of AEA binds to recombinant human CB1 and CB2 receptors with Ki values of 857 and 598 nM, respectively.

An endocannabinoid containing dihomo-&gamma-linoleate in place of the arachidonate moiety of AEA binds to recombinant human CB1 and CB2 receptors with Ki values of 857 and 598 nM, respectively.

An endocannabinoid containing dihomo-&gamma-linoleate in place of the arachidonate moiety of AEA binds to recombinant human CB1 and CB2 receptors with Ki values of 857 and 598 nM, respectively.

An endocannabinoid containing dihomo-&gamma-linoleate in place of the arachidonate moiety of AEA binds to recombinant human CB1 and CB2 receptors with Ki values of 857 and 598 nM, respectively.

Represents about 10% of the compound present in commercial preparations purporting to be pure capsaicin potency at VR1 appears equivalent to capsaicin.

Represents about 10% of the compound present in commercial preparations purporting to be pure capsaicin potency at VR1 appears equivalent to capsaicin.

Represents about 10% of the compound present in commercial preparations purporting to be pure capsaicin potency at VR1 appears equivalent to capsaicin.